A Two Part Phase IIa/b Multicentre Randomised Double-Blind Placebo-Controlled Parallel Group Dose-ranging Study to Assess Efficacy Safety and Tolerability of the Combination of Zibotentan and Dapagliflozin and Dapagliflozin Monotherapy Versus Placebo in Participants with Cirrhosis with Features of Portal Hypertension



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.